Hexagon Nutrition IPO has gained strong investor attention due to its robust subscription levels, improving profitability, and presence in the growing nutrition and wellness industry. The company operates across micronutrient premixes, clinical nutrition, and therapeutic nutrition products while exporting to more than 75 countries.
This Hexagon Nutrition IPO analysis covers the company's business model, financial performance, valuation, subscription status, GMP trends, key risks, and long-term investment outlook to help investors make an informed decision.
Table of Contents:
- Hexagon Nutrition IPO Details
- Hexagon Nutrition IPO Dates and Timeline
- About Hexagon Nutrition Limited
- Business Model and Revenue Segments
- Manufacturing Infrastructure and Global Reach
- Hexagon Nutrition Brand Portfolio
- Hexagon Nutrition Financial Performance
- Key Financial Ratios and KPIs
- Hexagon Nutrition IPO Structure Explained
- Hexagon Nutrition IPO Price, Lot Size and Investment Amount
- Hexagon Nutrition IPO Subscription Status
- Hexagon Nutrition IPO GMP and Listing Expectations
- Competitive Strengths Supporting Long-Term Growth
- Key Risks Every Investor Must Evaluate
- Hexagon Nutrition IPO Valuation Analysis
- Hexagon Nutrition IPO Review and Final Verdict
The Hexagon Nutrition IPO is a book-built public issue worth ₹138.87 crore. Unlike many recent public offerings that raise fresh capital for expansion, this issue is entirely an Offer for Sale. As a result, all proceeds will go to the existing selling shareholders and promoters rather than the company itself.
The issue opened for subscription on June 5, 2026 and closed on June 9, 2026. The company is scheduled to list on both NSE and BSE, making it accessible to a broad investor base.
Hexagon Nutrition IPO Details at a Glance
| Particular |
Details |
| IPO Size |
₹138.87 crore |
| Issue Type |
100% Offer for Sale |
| Price Band |
₹42 to ₹45 per share |
| Face Value |
₹1 per share |
| Lot Size |
333 shares |
| Minimum Investment |
₹14,985 |
| Post IPO Market Cap |
₹553 crore |
| Listing Exchange |
NSE & BSE |
The relatively small issue size and affordable share price have contributed to strong retail participation in the offering.
/content-assets/65c0b7e3797a471b947de9e3896c6656.png)
Get all the latest updates on the Hexagon Nutrition IPO, including offer details, price band, and institutional participation trends.
Investors tracking the Hexagon Nutrition IPO date and allotment process should note the following timeline.
| Event |
Date |
| IPO Opens |
June 5, 2026 |
| IPO Closes |
June 9, 2026 |
| Allotment Finalisation |
June 10, 2026 |
| Refund Initiation |
June 11, 2026 |
| Shares Credited |
June 11, 2026 |
| Listing Date |
June 12, 2026 (Tentative) |
The Hexagon Nutrition IPO listing date is currently scheduled for June 12, 2026, subject to regulatory and exchange approvals.
Hexagon Nutrition Limited is a Mumbai-based nutrition solutions company established in 1993. Over more than three decades, the company has evolved from a micronutrient formulations business into a diversified nutrition platform serving both domestic and international markets.
The company focuses on addressing nutritional deficiencies and health challenges through science-backed formulations. It develops products for food companies, healthcare institutions, government programmes, and consumers.
According to the CARE industry report referenced by the company, Hexagon Nutrition is among the few integrated nutrition companies in India offering solutions across the nutrition value chain, ranging from micronutrient premixes to therapeutic and clinical nutrition products.
Company Profile
| Particular |
Details |
| Incorporation Year |
1993 |
| Headquarters |
Mumbai |
| Managing Director |
Vikram Arun Kelkar |
| Joint Managing Director |
Nikhil Arun Kelkar |
| Manufacturing Facilities |
4 |
| Export Markets |
75+ Countries |
| R&D Centres |
2 |
| Industry |
Nutrition and Wellness |
The company serves customers across healthcare, food processing, dairy, wellness, nutrition, and public health sectors.
Understanding the business model is critical for any Hexagon Nutrition IPO analysis because the company operates across multiple nutrition categories rather than relying on a single product line.
Its business can broadly be divided into three major segments.
Premix Formulations
Premix formulations remain the largest contributor to revenue and form the foundation of the company's business.
These customised micronutrient blends are supplied to:
- FMCG companies
- Dairy cooperatives
- Beverage manufacturers
- Nutrition product companies
- Food processing businesses
For the nine months ended December 31, 2025, this segment contributed 51.47% of total revenue, generating approximately ₹137.73 crore.
The segment's leadership position gives Hexagon Nutrition a strong foothold in India's nutrition supply chain.
Branded Wellness and Clinical Nutrition
This segment caters directly to consumers and healthcare professionals.
The company markets products under established brands such as:
- Pentasure
- Obesigo
- Pediagold
- Nutrone
Demand in this category is supported by growing health awareness, preventive healthcare adoption, and rising clinical nutrition consumption.
Therapeutic and ESG Nutrition Products
This business includes products designed to combat malnutrition and nutritional deficiencies.
Key offerings include:
- Ready-to-Use Foods (RUFs)
- Micronutrient Powders (MNPs)
- Public health nutrition solutions
The company is recognised as one of the largest licensed suppliers of micronutrient powders under various international nutrition programmes.
A significant strength highlighted in the Hexagon Nutrition IPO review is its integrated manufacturing and international presence.
The company operates four manufacturing facilities:
| Facility Location |
Country |
| Nashik |
India |
| Chennai |
India |
| Thoothukudi |
India |
| Tashkent |
Uzbekistan |
These facilities allow the company to serve customers efficiently across domestic and international markets.
Exports have historically contributed more than half of total revenue, highlighting the company's global competitiveness.
The company exports to over 75 countries and maintains overseas offices in:
- South Africa
- Uzbekistan
- Hong Kong
This international footprint reduces dependence on any single geography and provides access to growing global nutrition markets.
Over the years, the company has developed multiple consumer-facing brands.
1. PENTASURE
Pentasure is the company's flagship clinical nutrition brand and is widely used in nutritional supplementation.
2. OBESIGO
Obesigo focuses on weight management and lifestyle nutrition products.
3. PEDIAGOLD
Pediagold addresses nutritional requirements in children and paediatric healthcare.
4. NUTRONE
Nutrone serves lifestyle and wellness-focused consumers seeking daily nutritional support.
The presence of recognised brands provides long-term opportunities for margin expansion and stronger consumer engagement.
One of the biggest positives in the Hexagon Nutrition IPO analysis is the company's strong profit growth and improving operating efficiency.
Revenue Growth
| Financial Year |
Revenue |
| FY23 |
₹278.50 crore |
| FY24 |
₹297.73 crore |
| FY25 |
₹324.93 crore |
| 9MFY26 |
₹267.59 crore |
Revenue increased steadily over the last three years, reflecting healthy demand across nutrition categories.
The company delivered an approximate revenue CAGR of 8% between FY23 and FY25.
Profit Growth
| Financial Year |
PAT |
| FY23 |
₹5.82 crore |
| FY24 |
₹12.21 crore |
| FY25 |
₹24.38 crore |
| 9MFY26 |
₹26.35 crore |
Profit growth has significantly outpaced revenue growth.
Net profit nearly quadrupled between FY23 and FY25, while PAT for the first nine months of FY26 already exceeded the entire FY25 figure.
The company delivered an impressive PAT CAGR of approximately 105% during FY23-FY25.
Margin Expansion
Margin improvement has been one of the strongest indicators of operational progress. Over the past few years, Hexagon Nutrition has consistently improved both its operating and net profit margins, reflecting better efficiency and stronger profitability.
EBITDA Margin Growth
| Period |
EBITDA Margin |
| FY23 |
8.0% |
| FY24 |
8.2% |
| FY25 |
12.6% |
| 9MFY26 |
14.0% |
PAT Margin Growth
| Period |
PAT Margin |
| FY23 |
2.1% |
| FY24 |
4.1% |
| FY25 |
7.5% |
| 9MFY26 |
9.81% |
The company's ability to improve margins despite raw material cost fluctuations and operational challenges demonstrates stronger execution, improved product mix, and better cost control. Sustained margin expansion has been one of the key drivers behind Hexagon Nutrition's sharp profit growth over the last three years.
The latest financial indicators further support the company's improving fundamentals.
| KPI |
Value |
| ROE |
13.02% |
| ROCE |
14.82% |
| EBITDA Margin |
14.03% |
| PAT Margin |
9.81% |
| Debt Equity Ratio |
0.18 |
| RoNW |
12.12% |
| NAV Per Share |
₹18.15 |
A debt-equity ratio of just 0.18 indicates a relatively conservative balance sheet compared to many growth-stage businesses.
One of the most important factors investors should understand is the structure of this public issue.
The Hexagon Nutrition IPO is entirely a 100% Offer for Sale.
What Does This Mean?
In a fresh issue IPO:
- Company receives money
- Capital can be used for expansion
- Debt can be reduced
- Capacity can be increased
In this IPO:
- Existing shareholders sell shares
- Company receives no funds
- No direct balance sheet improvement occurs
This does not automatically make the IPO unattractive, but investors should recognise that future growth will depend on existing resources and internal cash generation.
The Hexagon Nutrition IPO price band has been fixed between ₹42 and ₹45 per share.
Retail Investor Investment Requirement
| Category |
Requirement |
| Lot Size |
333 Shares |
| Issue Price |
₹45 |
| Minimum Investment |
₹14,985 |
HNI and NII Categories
| Category |
Minimum Investment |
| NII |
₹2,09,790 |
| BNII |
₹10,03,995 |
The low entry amount has made the issue accessible to retail investors.
The Hexagon Nutrition IPO subscription status reflects strong market interest across all investor categories.
Subscription Data
| Category |
Subscription |
| QIB |
19.77x |
| NII |
160.35x |
| Retail |
25.01x |
| Overall |
52.52x |
The exceptionally high NII participation indicates strong demand from high-net-worth investors.
Retail subscription of over 25 times also demonstrates meaningful investor confidence.
The Hexagon Nutrition IPO GMP has shown some moderation closer to listing.
GMP Trend
| Date |
GMP |
| June 5, 2026 |
₹14.44% Premium |
| June 9, 2026 |
₹3.5 Premium |
The decline in GMP suggests more conservative listing expectations despite strong subscription numbers.
Based on the latest GMP, investors may expect a modest listing gain rather than an exceptionally large debut premium.
However, GMP should never be viewed as a guaranteed indicator of listing performance.
Several factors strengthen the long-term investment case.
1. Integrated Nutrition Platform
The company controls multiple stages of the value chain:
- Research and development
- Manufacturing
- Quality assurance
- Regulatory compliance
- Distribution
This integrated model creates operational efficiencies and supports product innovation.
2. Strong Research and Development
The company operates two in-house R&D centres located in Nashik and Chennai.
During the nine months ended December 2025:
- 11 new products were developed
- Approximately 9 additional products were under development
Continuous innovation is critical in the nutrition industry where product differentiation drives growth.
3. Global Diversification
Exports to over 75 countries provide geographic diversification and reduce dependence on domestic demand cycles.
4. Distribution Strength
The company has built a broad distribution network including:
- 358+ distributors
- 167 sales professionals
- Access to 20,843+ healthcare professionals
This network supports both consumer and clinical nutrition businesses.
5. Strong Financial Momentum
Revenue growth, profit growth, margin expansion, and low leverage collectively strengthen the company's financial profile.
While the growth story is attractive, investors should not ignore the risks highlighted in the prospectus.
1. No Fresh Capital Through IPO
Because the issue is entirely OFS, the company receives no money from the IPO proceeds.
Future expansion will therefore rely on existing resources and future cash generation.
2. High Customer Concentration
The top 10 customers contributed 41.82% of revenue during the nine months ended December 2025.
Dependence on a limited number of clients creates earnings volatility if key relationships weaken.
3. Premix Segment Dependence
More than half of revenue comes from premix formulations.
Any slowdown in this segment could materially affect financial performance.
4. Quality Control Incidents
The company has faced operational challenges in the past.
Notable incidents include:
-
Salmonella contamination at the Thoothukudi facility in July 2023
-
Temporary suspension lasting approximately seven months
-
Product batch destruction linked to formulation errors
These incidents highlight the importance of quality control in nutrition manufacturing.
5. Nashik Facility Reconstruction
The Nashik facility is undergoing partial reconstruction and regulatory upgrades.
This process may affect production capacity and operational efficiency in the near term.
6. Negative Operating Cash Flows
The company operates with a working capital cycle of approximately 149 days.
Large receivables can put pressure on cash flows despite reported profits.
7. Raw Material Price Volatility
Changes in input costs may affect margins if increases cannot be passed on to customers.
At the upper price band of ₹45, the valuation appears relatively reasonable considering the company's earnings growth.
Valuation Snapshot
| Metric |
Value |
| IPO Price |
₹45 |
| Post IPO EPS |
₹2.93 |
| Post IPO P/E |
15.4x |
| NAV Per Share |
₹18.15 |
| Price to NAV |
2.48x |
A post-IPO P/E of approximately 15.4x appears moderate when compared with many listed nutrition and healthcare companies.
The valuation is significantly supported by the company's improving profitability and expanding margins.
Want to compare Hexagon Nutrition with other recently listed healthcare, wellness, and manufacturing companies? Use this IPO dashboard for valuation and subscription benchmarking.
The Hexagon Nutrition IPO presents a mixed but interesting investment opportunity.
On one hand, the company offers exposure to a structurally growing nutrition market, has a diversified product portfolio, exports to more than 75 countries, maintains a low debt profile, and has delivered impressive profit growth over recent years.
On the other hand, investors must carefully consider the fact that the IPO is entirely an Offer for Sale, customer concentration remains elevated, quality control issues have occurred in the past, and operating cash flow remains under pressure due to working capital requirements.
Investment Assessment
| Factor |
Assessment |
| Financial Growth |
Strong |
| Profitability Trend |
Improving |
| Debt Position |
Comfortable |
| Subscription Demand |
Very Strong |
| Listing Gain Potential |
Moderate |
| Long-Term Opportunity |
Positive |
| Risk Profile |
Above Average |
For investors seeking short-term listing gains, the strong subscription status provides some support, although the latest Hexagon Nutrition IPO GMP suggests gains may be moderate rather than exceptional.
For long-term investors, the opportunity depends largely on management's ability to sustain margin expansion, improve cash flow generation, diversify its customer base, and maintain high product quality standards.
Overall, the Hexagon Nutrition IPO analysis suggests a fundamentally improving business with attractive industry exposure, but one that also requires careful consideration of execution and operational risks before investing.